GlassScriptPhysician profile
Brian K Gaw
NPI 1457354391
$2,698.71
in general payments reported to CMS, 2019-2025
24 companies · $1,114 in 2025
The $1,114 reported for 2025 was more than what 98% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $240 · 2021: $101 · 2022: $316 · 2023: $308 · 2024: $499 · 2025: $1,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,921.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $384.60 | 2024-2025 | Ycanth |
| Sobi, INC | $210.16 | 2019-2023 | |
| Supernus Pharmaceuticals, INC. | $192.67 | 2022-2025 | Qelbree, Qelbree |
| Glaxosmithkline, LLC. | $191.27 | 2019-2023 | Rotarix, Bexsero |
| Corium, LLC | $189.17 | 2023-2025 | Azstarys |
| Neurelis, INC. | $185.95 | 2025 | Valtoco |
| Kowa Pharmaceuticals America, INC. | $181.86 | 2024-2025 | Zoryve |
| Pfizer INC. | $149.40 | 2019-2024 | |
| Sanofi Pasteur INC. | $135.08 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $123.37 | 2020-2025 | Vaxelis, Gardasil 9, Vaxneuvance |
| Acadia Pharmaceuticals INC | $101.49 | 2025 | Daybue |
| Cranial Technologies, INC | $100.08 | 2022-2025 | Doc Band |
| Ars Pharmaceuticals Operations, INC. | $84.00 | 2025 | Neffy |
| Ironshore Pharmaceuticals INC. | $72.40 | 2019-2024 | |
| Collegium Pharmaceutical, INC. | $66.51 | 2025 | Jornay Pm |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $64.70 | 2022-2024 | |
| Ultragenyx Pharmaceutical INC. | $61.15 | 2020-2021 | |
| Metacel Pharmaceuticals LLC | $51.38 | 2024-2025 | Ozobax, Ozobax |
| Mirum Pharmaceuticals, INC. | $39.47 | 2023-2024 | Cholbam, Livmarli |
| Lilly USA, LLC | $32.02 | 2023 | Mounjaro |
| Kyowa Kirin, INC. | $28.69 | 2023 | |
| Genzyme Corporation | $20.86 | 2023 | |
| Jazz Pharmaceuticals INC. | $18.45 | 2025 | |
| Phadia US INC. | $13.98 | 2024 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Gaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.